MBD2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, GSK-J4 treatment did not affect the sensitivity of K562 cells to imatinib (Figure 2B), implying that the demethylase activity of KDM6A is dispensable for protection of CML cells against imatinib.